5-methyl-6-trifluoromethyl-2,3-dihydro-indole-1-carboxylic acid [6-(2-methyl-pyridin-3-yloxy)-pyridin-3-yl]-amide | 200940-22-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 5-methyl-6-trifluoromethyl-2,3-dihydro-indole-1-carboxylic acid [6-(2-methyl-pyridin-3-yloxy)-pyridin-3-yl]-amide
• 英文别名: SB 243213；DIV04892；5-Methyl-6-trifluoromethyl-1-[6-(2-methylpyridin-3-yloxy)-pyridin-3-ylcarbamoyl]indoline；5-methyl-N-[6-(2-methylpyridin-3-yl)oxypyridin-3-yl]-6-(trifluoromethyl)-2,3-dihydroindole-1-carboxamide
• CAS: 200940-22-3
• 化学式: C₂₂H₁₉F₃N₄O₂
• 分子量: 428.414
• InChiKey: ZETBBVYSBABLHL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  31
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  67.4
• 氢给体数：
  1
• 氢受体数：
  7

制备方法与用途

生物活性

SB 243213 是一种口服有效的、选择性的高亲和力 5-HT2C 受体拮抗剂，对人 5-HT2C 受体的 pKi 值为 9.37，pKb 值为 9.8。SB 243213 对多种神经递质受体、酶和离子通道的选择性超过 100 倍，并展现出改善的抗焦虑特性，有用于精神分裂症和运动障碍治疗的潜力。

靶点

Human 5-HT_2C 受体: 9.37 (pKi)

5-HT受体	pKi值
Human 5-HT1A Receptor	<5.3
Human 5-HT1B Receptor	5.5
Human 5-HT1D Receptor	6.32
Human 5-HT1E Receptor	<5.4
Human 5-HT1F Receptor	5.35
Human 5-HT2A Receptor	7.01
Human 5-HT2B Receptor	7.2
Human 5-HT6 Receptor	6.5
Human 5-HT7 Receptor	5.64

体外研究

SB 243213 对克隆的人类 5-HT1A、5-HT1B、5-HT1E 和 5-HT1F 受体以及 5-HT7 受体的亲和力较低 (pKi <6)。它对人类 5-HT1D 和 D3 受体的亲和力较弱 (pKi <6.5)，并对克隆的人类 D2 受体表现出中等亲和力 (pKi =6.7)。

体内研究

SB 243213（0.1-10 mg/kg，口服；给药前 1 小时）剂量依赖性地且显著增加了在明亮光照条件下及陌生测试箱内停留时间超过 15 分钟的雄性 Sprague-Dawley 大鼠的社会互动时间。SB 243213（0.3 mg/kg，口服；给药前 1 小时）显著增加了社会互动的时间。

| 动物模型 | 雄性 Sprague-Dawley 大鼠 (未经过训练的实验大鼠)，体重在 220-300 g | | 剂量 | 0.1, 0.3, 1, 3, 10 mg/kg | | 给药途径 | 口服；给药前 1 小时 | | 结果 | 剂量依赖性地且显著增加了在明亮光照条件下及陌生测试箱内停留时间超过 15 分钟的雄性 Sprague-Dawley 大鼠的社会互动时间。 |

反应信息

• 作为产物：
  描述：

  6-[(2-甲基-3-吡啶)氧基]-3-吡啶胺 在 三乙胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 5-methyl-6-trifluoromethyl-2,3-dihydro-indole-1-carboxylic acid [6-(2-methyl-pyridin-3-yloxy)-pyridin-3-yl]-amide
  参考文献：
  名称：

  Biarylcarbamoylindolines Are Novel and Selective 5-HT_2C Receptor Inverse Agonists:  Identification of 5-Methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a Potential Antidepressant/Anxiolytic Agent

  摘要：

  The evolution, synthesis, and biological activity of a novel series of 5-HT2C receptor inverse agonists are reported. Biarylcarbamoylindolines have been identified with excellent 5-HT2C affinity and selectivity over 5-HT2A receptors. In addition, (pyridyloxypyridyl)carbamoylindolines have been discovered with additional selectivity over the closely related 5-HT2B receptor. Compounds from this series are inverse agonists at the human cloned 5-HT2C receptor, completely abolishing basal activity in a functional assay. The new series have reduced P450 inhibitory liability compared to a previously described series of 1-(3-pyridylcarbamoyl)indolines (Bromidge et al. J. Med. Chem. 1998, 41, 1598) from which they evolved. Compounds from this series showed excellent oral activity in a rat mCPP hypolocomotion model and in animal models of anxiety. On the basis of their favorable biological profile, 32 (SB-228357) and 40 (SB-243213) have been selected for further evaluation to determine their therapeutic potential for the treatment of CNS disorders such as depression and anxiety.

  DOI：

  10.1021/jm990388c

文献信息

• NOVEL INDOL CARBOXYLIC ACID BISPYRIDYL CARBOXAMIDE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD AND COMPOSITION CONTAINING THE SAME AS AN ACTIVE INGREDIENT
  申请人：SEONG Churlmin

  公开号：US20090258876A1

  公开（公告）日：2009-10-15

  Disclosed herein are a new indole carboxylic acid bispyridyl carboxamide derivative, a preparation method thereof, and a composition for prevention or treatment of obesity, urinary disorders, and CNS disorders, containing the same as an active ingredient. Because the indole carboxylic acid bispyridyl carboxamide derivatives according to the present invention have high affinity for 5-HT 2c receptors, act selectively on the 5-HT 2c receptors, the derivatives rarely have adverse effects caused by other receptors. Because the derivatives effectively inhibit serotonin activity, they may be useful for treatment or prevention of obesity; urinary disorders such as urinary incontinence, premature ejaculation, erectile dysfunction, and prostatic hyperplasia; CNS disorders such as depression, anxiety, concern, panic disorder, epilepsy, obsessive-compulsive disorder, migraine, sleep disorder, withdrawal from drug abuse, Alzheimer's disease, and schizophrenia, associated with 5-HT 2c receptors.

  本公开涉及一种新的吲哚羧酸双吡啶羧酰胺衍生物，其制备方法，以及包含该衍生物作为活性成分的用于预防或治疗肥胖、泌尿系统疾病和中枢神经系统疾病的组合物。根据本发明的吲哚羧酸双吡啶羧酰胺衍生物具有高亲和力5-HT2c受体，对5-HT2c受体选择性作用，这些衍生物很少出现由其他受体引起的不良反应。由于这些衍生物有效抑制5-羟色胺活性，它们可能对治疗或预防肥胖；泌尿系统疾病，如尿失禁、早泄、勃起功能障碍和前列腺增生；以及与5-HT2c受体相关的中枢神经系统疾病，如抑郁症、焦虑症、关注症、恐慌症、癫痫、强迫症、偏头痛、睡眠障碍、戒毒、阿尔茨海默病和精神分裂症可能有用。
• Indoline derivatives useful as 5-HT-2C receptor antagonists
  申请人：SmithKline Beecham p.l.c.

  公开号：US06369060B1

  公开（公告）日：2002-04-09

  The invention relates to compounds of formula (I) or a salt thereof wherein X is CH or N; R1 is hydrogen or C1-6 alkyl; R2 and R3 groups are independently C1-6 alkyl, or trifluoromethyl, having pharmacological activity, processes for their preparation, compositions containing them and to their use in the treatment of CNS disorders such as anxiety.

  本发明涉及公式（I）的化合物或其盐，其中X为CH或N；R1为氢或C1-6烷基；R2和R3基团独立地为C1-6烷基或三氟甲基，具有药理活性，其制备过程，含有它们的组合物以及它们在治疗中枢神经系统疾病如焦虑症中的应用。
• [EN] INDOLINE DERIVATIVES USEFUL AS 5-HT-2C RECEPTOR ANTAGONISTS<br/>[FR] DERIVES DE L'INDOLINE UTILES COMME ANTAGONISTES DES RECEPTEURS 5HT-2C
  申请人：SMITHKLINE BEECHAM PLC

  公开号：WO1997048699A1

  公开（公告）日：1997-12-24

  (EN) The invention relates to heterocyclic compounds of formula (I) or a salt thereof wherein X is CH or N; R1 is hydrogen or C1-6 alkyl; R2 and R3 groups are independently halogen, C1-6 alkyl, or trifluoromethyl, having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of CNS disorders such as anxiety.(FR) L'invention concerne des composés hétérocycliques de formule (I), dans laquelle X est CH ou N; R1 est hydrogène ou alkyle C1-C6; et les groupes R2 et R3 sont indépendamment halogène, alkyle C1-C6 ou trifluorométhyle; et leurs sels; ces composés ayant une activité pharmacologique. L'invention concerne également des procédés permettant de les préparer et des compositions les contenant, ainsi que leur utilisation dans le traitement des troubles du système nerveux central tels que l'angoisse.

  该发明涉及公式（I）的杂环化合物或其盐，其中X为CH或N; R1为氢或C1-6烷基; R2和R3基团独立地为卤素，C1-6烷基或三氟甲基，具有药理活性，其制备过程，含有它们的组合物以及它们在治疗如焦虑症等中枢神经系统疾病中的用途。
• NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION
  申请人：Barlow Carrolee

  公开号：US20070049576A1

  公开（公告）日：2007-03-01

  The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on muscarinic receptor modulation, such as via inhibition of acetylcholine esterase (AChE) activity, alone or in combination with another neurogenic agent to stimulate or activate the formation of new nerve cells.

  该即时披露描述了通过刺激或增加神经发生来治疗中枢神经系统和外周神经系统的疾病和病症的方法。该披露包括基于毒蕈碱受体调节的组合物和方法，例如通过抑制乙酰胆碱酯酶（AChE）活性，单独或与另一种神经生成剂结合以刺激或激活新神经细胞的形成。
• Neurogenesis by muscarinic receptor modulation with sabcomelin
  申请人：Braincells, Inc.

  公开号：EP2258359A2

  公开（公告）日：2010-12-08

  The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on muscarinic receptor modulation, such as via inhibition of acetylcholine esterase (AChE) activity, alone or in combination with another neurogenic agent to stimulate or activate the formation of new nerve cells.

  本公开描述了通过刺激或增加神经发生来治疗中枢和周围神经系统疾病和病症的方法。本公开包括基于毒蕈碱受体调节的组合物和方法，例如通过抑制乙酰胆碱酯酶（AChE）活性，单独或与另一种神经发生剂联合使用，以刺激或激活新神经细胞的形成。